1-4
Mini Review
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib
Judith Meza-Junco, Quincy S.-C. Chu, Olaf Christensen, Prabhu Rajagopalan and Soma Das, et al.
5-12
Original Article
Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines
Dhana E. Larsson, Sadia Hassan, Rolf Larsson, Kjell Öberg and Dan Granberg
13-25
Original Article
PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin
Zhu Yuan, Fei Yan, Yong-sheng Wang, Huan-yi Liu and Lan-tu Gou, et al.
27-32
Original Article
Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
Byoung Chul Cho, Ki Chang Keum, Sang Joon Shin, Hye Jin Choi and Young Joo Lee, et al.
33-40
Original Article
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors
Josephia R. Muindi, Candace S. Johnson, Donald L. Trump, Renee Christy and Kristie L. Engler, et al.
41-54
Original Article
ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress
Adrienne N. Howard, Kathleen A. Bridges, Raymond E. Meyn and Joya Chandra
55-66
Original Article
Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
Punit H. Marathe, Amrita V. Kamath, Yueping Zhang, Celia D’Arienzo and Rajeev Bhide, et al.
67-71
Original Article
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients
Barrie R. Cassileth, Naiyer Rizvi, Gary Deng, K. Simon Yeung and Andrew Vickers, et al.
73-78
Original Article
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers
Afshin Dowlati, James Posey, Ramesh K. Ramanathan, Linda Rath and Pingfu Fu, et al.
79-88
Original Article
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer
Noboru Yamamoto, Tomohide Tamura, Takayasu Kurata, Nobuyuki Yamamoto and Ikuo Sekine, et al.
89-96
Original Article
Biological reactive intermediates that mediate dacarbazine cytotoxicity
Jalal Pourahmad, Marzieh Amirmostofian, Farzad Kobarfard and Jafar Shahraki
97-105
Original Article
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors
Crystal S. Denlinger, Rebecca Blanchard, Lu Xu, Coen Bernaards and Samuel Litwin, et al.
107-112
Original Article
Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer
Muhammad Wasif Saif, K. I. Syrigos, S. Hotchkiss, J. Shanley and J. Grasso, et al.
113-120
Original Article
A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer
Junji Furuse, Takuji Okusaka, Shinichi Ohkawa, Michitaka Nagase and Akihiro Funakoshi, et al.
121-128
Original Article
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors
Zacharenia Saridaki, Periklis Pappas, John Souglakos, Martha Nikolaidou and Nikolaos Vardakis, et al.
129-136
Original Article
Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
Nobuyuki Yamamoto, Narikazu Boku and Hironobu Minami
137-142
Original Article
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors
Holly J. Meany, Katherine E. Warren, Elizabeth Fox, Diane E. Cole and Alberta A. Aikin, et al.
143-150
Original Article
The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway
Takeshi Akiyoshi, Sumio Matzno, Mika Sakai, Noboru Okamura and Kenji Matsuyama
151-157
Original Article
A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma
Jen-Shi Chen, Yee Chao, Tseng-Sheng Yang, Wen-Chi Chou and Li-Tzong Chen, et al.
159-166
Original Article
Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer
Sung-Ji Lee, Sang-Hee Cho, Ju-Young Yoon, Jun-Eul Hwang and Woo-Kyun Bae, et al.
167-175
Original Article
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
Chia-Chi Lin, Muralidhar Beeram, Eric K. Rowinsky, Chris H. Takimoto and Chee M. Ng, et al.
177-186
Original Article
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent
Amy W. Chun, Stephen C. Cosenza, David R. Taft and Manoj Maniar
187-190
Short Communication
Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature
Jose Ortega, J. Michael Hayes and Scott Antonia
191-195
Short Communication
The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer
K. Dredge, J. A. Kink, R. M. Johnson, I. Bytheway and L. J. Marton
197-199
Short Communication
K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment?
Maria Giulia Zampino, Elena Magni, Angelica Sonzogni and Giuseppe Renne